Chen Ishita, Wu Abraham J, Jackson Andrew, Patel Purvi, Sun Lian, Ng Angela, Iyer Aditi, Apte Aditya, Rimner Andreas, Gomez Daniel, Deasy Joseph O, Thor Maria
Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, United States.
Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, NYv.
Clin Transl Radiat Oncol. 2022 Nov 4;38:57-61. doi: 10.1016/j.ctro.2022.10.012. eCollection 2023 Jan.
Pulmonary toxicity is dose-limiting in stereotactic body radiation therapy (SBRT) for tumors that abut the proximal bronchial tree (PBT), esophagus, or other mediastinal structures. In this work we explored published models of pulmonary toxicity following SBRT for such ultracentral tumors in an independent cohort of patients.
The PubMed database was searched for pulmonary toxicity models. Identified models were tested in a cohort of patients with ultracentral lung tumors treated between 2008 and 2017 at one large center (N = 88). This cohort included 60 % primary and 40 % metastatic tumors treated to 45 Gy in 5 fractions (fx), 50 Gy in 5 fx, 60 Gy in 8 fx, or 60 Gy in 15 fx prescribed as 100 % dose to PTV.
Seven published NTCP models from two studies were identified. The NTCP models utilized PBT max point dose (Dmax), D0.2 cm, V65, V100, and V130. Within the independent cohort, the ≥ grade 3 toxicity and grade 5 toxicity rates were 18 % and 7-10 %, respectively, and the Dmax models best described pulmonary toxicity. The Dmax to 0.1 cm model was better calibrated and had increased steepness compared to the Dmax model. A re-planning study minimizing PBT 0.1 cm to below 122 Gy in EQD2 (for a 10 % ≥grade 3 pulmonary toxicity) was demonstrated to be completely feasible in 4/6 patients, and dose to PBT 0.1 cm was considerably lowered in all six patients.
Pulmonary toxicity models were identified from two studies and explored within an independent ultracentral lung tumor cohort. A modified Dmax to 0.1 cm PBT model displayed the best performance. This model could be utilized as a starting point for rationally constructed airways constraints in ultracentral patients treated with SBRT or hypofractionation.
对于紧邻近端支气管树(PBT)、食管或其他纵隔结构的肿瘤,立体定向体部放射治疗(SBRT)中的肺部毒性是剂量限制因素。在本研究中,我们在一个独立的患者队列中探索了已发表的关于此类超中心型肿瘤SBRT后肺部毒性的模型。
在PubMed数据库中搜索肺部毒性模型。在一个大型中心(N = 88)对2008年至2017年间治疗的超中心型肺肿瘤患者队列中测试已识别的模型。该队列包括60%的原发性肿瘤和40%的转移性肿瘤,接受5次分割(fx)45 Gy、5次分割50 Gy、8次分割60 Gy或15次分割60 Gy的治疗,规定PTV的剂量为100%。
从两项研究中识别出七个已发表的正常组织并发症概率(NTCP)模型。NTCP模型使用了PBT最大点剂量(Dmax)、D0.2 cm、V65、V100和V130。在独立队列中,≥3级毒性和5级毒性发生率分别为18%和7 - 10%,Dmax模型对肺部毒性的描述最佳。与Dmax模型相比,Dmax至0.1 cm模型校准更好且陡峭度增加。一项重新计划研究显示,将PBT 0.1 cm在等效剂量(EQD2)中降至122 Gy以下(对于10%的≥3级肺部毒性)在4/6例患者中完全可行,并且所有6例患者的PBT 0.1 cm剂量均显著降低。
从两项研究中识别出肺部毒性模型,并在一个独立的超中心型肺肿瘤队列中进行了探索。改良的PBT 0.1 cm Dmax模型表现最佳。该模型可作为在接受SBRT或大分割放疗的超中心型患者中合理构建气道限制的起点。